Kerin B. Adelson, MD, of the Yale Cancer Center, discusses the major healthcare cost drivers at the end of life—aggressive treatments, emergency room visits, and futile care—and strategies for improving value. (Abstract 3)
Steven Shak, MD, of Genomic Health, discusses mortality among patients with early-stage hormone receptor–positive invasive breast cancer in the SEER database who were treated based on the 21-gene Recurrence Score results (Abstract 176).
Kerin B. Adelson, MD, of the Yale Cancer Center, discusses an electronic decision support tool to capture staging data. This information allows automated reports for clinical trial screening, outcomes analysis, quality comparisons, and reporting. (Abstract 151)
Lee N. Newcomer, MD, of the UnitedHealth Group, gives his perspective on how to assess quality in the age of precision medicine.
Dawn L. Hershman, MD, of Columbia University Medical Center, summarizes a joint ASCO/NCI session on this important topic, including the challenges and solutions.
Monika K. Krzyzanowska, MD, of Princess Margaret Cancer Centre, summarizes a session that she co-chaired on this key topic.
